EdwardBrianGaronMD
Oncology • Santa Monica, CAHematologic Oncology
Assistant Professor, Medicine, UCLA School of Medicine
Dr. Garon is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2020 Santa Monica Blvd.
Suite 600
Santa Monica, CA 90404Phone(310) 829-5471
Fax(310) 586-0841- Is this information wrong?
Education & Training
UCLA Medical CenterFellowship, Hematology/Oncology, 2003 - 2006
University of ChicagoResidency, Internal Medicine, 1999 - 2002
Washington University School of Medicine in St. LouisClass of 1999
Certifications & Licensure
CA State Medical License 2003 - 2022
IL State Medical License 1999 - 2005- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Start of enrollment: 2016 Sep 01Edward Garon
- Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2014 Jan 01Garon, E.
- Phase I Dose Escalation Study of Carboplatin, Pemetrexed and Exemestane in Post-menopausal Women With Metastatic Non-squamous NSCLC Start of enrollment: 2012 Sep 01Garon, E.B.
- A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer Start of enrollment: 2009 Dec 01Garon, E.B.
- Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 01Garon, E.
- Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Jan 01Garon, E.
- Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Oct 01Garon, E.
- Join now to see all
Publications & Presentations
PubMed
- Severity of COVID-19 in patients with lung cancer: evidence and challenges.Antonio Passaro, Christine M. Bestvina, Maria Velez Velez, Marina Chiara Garassino, Edward B. Garon, Solange Peters> ;Journal for ImmunoTherapy of Cancer. 2021 Mar 1
- Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.Edward B. Garon, Paige Brodrick> ;Drugs. 2021 Feb 27
- Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.Edward B. Garon, Joachim G.J.V. Aerts, Jong Seok Kim, Catherine Muehlenbein, Patrick Peterson, Maria Teresa Rizzo, S. Gadgeel> ;Lung Cancer. 2021 Feb 19
- Join now to see all
Journal Articles
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung CancerEdward B Garon, Maeve Waldron-Lynch, The New England Journal of Medicine
Lectures
- Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.2019 ASCO Annual Meeting - 6/1/2019
- Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
- New Lung Cancer Treatments Lead to Vastly Improved Survival RatesNovember 6th, 2020
Lilly's CYRAMZA® (Ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in the Lancet OncologyDecember 13th, 2019
Ramucirumab, Erlotinib Combo a Promising First-Line EGFR-Mutated NSCLC TreatmentOctober 9th, 2019- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Ronald Reagan UCLA Medical CenterLos Angeles, California
UCLA Medical Center-Santa MonicaSanta Monica, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
